FDA Approves Bixlenvo, a Daily HIV Pill from Gilead, to Simplify Treatment for Select Patients

The U.S. Food and Drug Administration has given the green light to a new once-daily HIV pill developed by Gilead, a move expected to streamline care for certain individuals living with the virus. This new medication, known as Bixlenvo, is intended for patients whose viral load is already under control but who are currently on more complex treatment plans, or for those who simply wish to switch to a different therapeutic option.

Bixlenvo is a single-tablet regimen that combines bictegravir, a key component in Gilead's highly successful Biktarvy HIV pill, with lenacapavir. Lenacapavir is a groundbreaking first-in-class capsid inhibitor that has become a central element of Gilead's long-term strategy for both HIV treatment and prevention.

According to Gilead, this approval marks the introduction of the first single-tablet regimen available for adults with HIV whose virus is suppressed but who cannot use existing one-pill treatment options. This specific patient group is estimated to represent at least 5% of individuals living with HIV in the United States.

The list price for a 30-day supply of Bixlenvo, before any discounts or rebates, is set at $4,595, a figure comparable to other existing daily single-tablet HIV treatments. Gilead has indicated that individuals without health insurance may be eligible to receive Bixlenvo at no cost through the company's patient assistance program. Those with commercial or private insurance might also qualify for co-pay assistance through a separate savings program.

Dr. Jared Baeten, head of Gilead's clinical development and virology therapeutic area, highlighted that the new pill addresses a significant unmet need, particularly for patients on complicated regimens who would benefit from consolidation into a more manageable treatment. He also noted its appeal to individuals seeking new treatment alternatives, emphasizing Gilead's commitment to providing options that suit individual needs for the long term.

While there is no cure for HIV or AIDS, many people living with HIV can effectively manage the disease with a daily single pill, a treatment approach that Gilead helped to advance two decades ago. However, some patients face challenges with current one-tablet options due to drug resistance developed from older therapies, side effects, or interactions with other medications. These individuals may require multiple pills daily and complex dosing schedules.

Dr. Baeten explained that this patient group often includes older individuals with extensive treatment histories, some of whom have taken numerous pills daily for many years. He also pointed out that HIV can accelerate age-related health issues like heart disease, diabetes, and high cholesterol in this demographic, underscoring the importance of developing treatments for individuals aging with HIV.

Bixlenvo is also designed for individuals who are managing their HIV well on a single-tablet regimen, such as Biktarvy, and are interested in switching to a new option. Dr. Baeten clarified that Bixlenvo is not intended to replace Biktarvy but rather to expand treatment choices. He stressed the highly individualized nature of HIV care, where long-term success often hinges on finding a regimen that best aligns with a patient's preferences and lifestyle.

Furthermore, Bixlenvo is part of Gilead's broader initiative to develop a diverse range of HIV treatment options centered around lenacapavir, including daily pills, weekly oral regimens, and long-acting injectable therapies. The overarching goal is to offer patients greater flexibility and choice in how they manage their condition.

Dr. Baeten elaborated that the aim is to provide enough options so that individuals can select the treatment that works best for them, whether it's the predictability of a daily pill or the convenience of a less frequent administration method.

What Bixlenvo is like for patients

Dr. Baeten emphasized the necessity of having multiple medications for treating HIV, as the virus can develop resistance to initial treatments. He explained that the combination of bictegravir and lenacapavir in a single pill allows the treatment to target the virus in two distinct ways, offering high efficacy and robust protection against the development of drug resistance.

The approval of Bixlenvo is based on findings from two Phase 3 clinical trials, ARTISTRY-1 and a related study, which assessed the drug in adult patients with HIV whose viral load was already suppressed. These trials included participants who switched from Biktarvy or complex multi-tablet regimens.

The ARTISTRY-1 trial specifically enrolled patients with long treatment histories and evidence of drug resistance, many of whom were taking multiple HIV medications daily. Participants in this trial had a median age of 60 and were taking between two and 11 pills daily before transitioning to Bixlenvo.

In both studies, Bixlenvo successfully maintained viral suppression at 48 weeks, achieving rates comparable to patients' previous regimens. The drug was generally well-tolerated, with no new safety concerns identified. The most frequently reported side effects, occurring in at least 2% of participants, included headache, nausea, and diarrhea.

Timothy Cameron, a 64-year-old retired resident of Seattle who has lived with HIV for over 40 years, was a participant in the ARTISTRY-1 Phase 3 trial. He recounted his experiences starting in the 1980s, when treatment options were limited and viral load measurement was rudimentary. Over the decades, Cameron cycled through various HIV medications, experimental drugs, and multi-pill regimens, often enduring difficult side effects and encountering treatments that eventually became ineffective against his “hard-to-treat” virus.

"It was like throwing darts at a dartboard," Cameron said. "Because I had done so many drug trials and monotherapy, my virus had become super resistant."

A few years prior to joining the Gilead study, Cameron found a regimen that controlled his virus, though it required taking one HIV pill twice daily along with another medication. His doctor encouraged him to enroll in the trial and switch to Bixlenvo, a once-daily pill he described as "smaller than my pinky nail."

Cameron reported a seamless transition. The drug effectively maintained viral control without adverse side effects and significantly simplified his treatment routine by reducing his pill count and consolidating his medications into a single daily schedule. For Cameron, who spent decades navigating limited and increasingly ineffective treatment options due to viral resistance, a key benefit of the two-drug regimen is its ability to control his virus while exposing him to fewer medications. This, he feels, provides him with confidence that additional treatment options will remain available in the future should he need them.

"It's one less thing I'm putting in my body, and it preserves options if I need them," Cameron stated.